These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 30581511

  • 1. Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.
    You R, Qian X, Tang W, Xie T, Zeng F, Chen J, Zhang Y, Liu J.
    Can Respir J; 2018; 2018():1015239. PubMed ID: 30581511
    [Abstract] [Full Text] [Related]

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 3. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G, Mehta S.
    Appl Health Econ Health Policy; 2009 Oct; 7(1):43-59. PubMed ID: 19558194
    [Abstract] [Full Text] [Related]

  • 4. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL, Shields KM.
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [Abstract] [Full Text] [Related]

  • 5. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE.
    Respiration; 2017 Nov; 94(1):26-37. PubMed ID: 28494463
    [Abstract] [Full Text] [Related]

  • 6. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q, Guo N, Chen J, Parks D, Tian Z.
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [Abstract] [Full Text] [Related]

  • 7. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A, Barberà JA, Escribano P, Sala ML, Febrer L, Oyagüez I, Sabater E, Casado MA.
    Appl Health Econ Health Policy; 2012 May 01; 10(3):175-88. PubMed ID: 22452448
    [Abstract] [Full Text] [Related]

  • 9. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
    Heresi GA, Love TE, Tonelli AR, Highland KB, Dweik RA.
    Am J Respir Crit Care Med; 2018 Oct 15; 198(8):1090-1093. PubMed ID: 29949380
    [No Abstract] [Full Text] [Related]

  • 10. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
    Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG.
    Eur J Cardiovasc Nurs; 2018 Oct 15; 17(7):612-618. PubMed ID: 29641223
    [Abstract] [Full Text] [Related]

  • 11. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R.
    Value Health; 2009 Oct 15; 12(8):1100-5. PubMed ID: 19558373
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.
    BMC Cardiovasc Disord; 2010 Feb 22; 10():9. PubMed ID: 20170553
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
    Chen T, Chen J, Chen C, Zheng H, Chen Y, Liu M, Zheng B.
    Pediatr Pulmonol; 2021 Jul 22; 56(7):2250-2258. PubMed ID: 33856119
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H, Hara T, Tsuji M, Saito A, Minatsuki S, Inaba T, Amiya E, Hosoya Y, Hatano M, Morita H, Yao A, Kinugawa K, Komuro I.
    Int Heart J; 2020 Jul 22; 61(4):799-805. PubMed ID: 32728000
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, Fukuda K.
    BMC Pulm Med; 2015 May 14; 15():62. PubMed ID: 25971443
    [Abstract] [Full Text] [Related]

  • 20. Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.
    Chen Y, Li F, Luo J, Chen J, Luo P, Li J.
    Can Respir J; 2021 May 14; 2021():1626971. PubMed ID: 34512819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.